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Abstract: Countries struggling to fund new premium priced medicines with ever increasing prices. In 
addition, substantial savings as medicines lose their patents. This requires co-ordinated approaches. 
Models are being developed centring on three pillars: pre-launch including horizon scanning; peri-
launch including P & R/ risk sharing; post-launch including assessing effectiveness. This will continue 
to enable access to safe, effective and affordable medicines. 
 
Introduction: Countries are struggling to fund new premium priced medicines with ever increasing 
prices. In addition, substantial savings as medicines lose their patents. This requires co-ordinated 
approaches. Models are being developed centring on three pillars: pre-launch including horizon 
scanning; peri-launch including P & R/ risk sharing; post-launch including assessing effectiveness 
[1,2]. This will continue to enable access to safe, effective and affordable medicines. 
 
Methodology: Desk research of regulatory and other relevant policy documents as well as a thorough 
and extensive literature search in peer-reviewed databases. 
 
Results: Models to optimise the use of new medicines are being developed. These centre on three 
pillars: pre-launch activities including horizon VFDQQLQJZLWKDVSHFLILFIRFXVRQXQPHWQHHGVGUXJV¶
H[SHFWHGSODFHLQWKHUDS\GUXJV¶SUHOLPLQDU\EXGJHWLPSDFWDQGIRUHFDVWLQJLQFOXGLQJPHGLFLQHV
likely to lose their patents); peri-launch activities including P & R assessment and assessments of risk 
sharing arrangements; post-launch activities include assessing the effectiveness and safety of new 
medicines in routine clinical care [1,2]. Pre-launch activities to agree the number of potential patients 
for new cancer medicines resulted in hospitals staying within budget [3]; and health authorities that 
had instigated activities pre-launch saw limited excess bleeding with dabigatran [3]. Risk-sharing 
arrangements have increased access to new medicines; however, concerns with their confidential 
nature and administrative burden [2,3]. Qualitative and/or quantitative approaches are also being 
developed to better value (new) medicines. There is also growing use of patient level data post 
launch, e.g. studies highlighted concerns with dabigatran prescribing in Spain and anti-obesity 
medicines in Sweden. Long-term follow-up studies have shown greater effectiveness of ciclosporin 
vs. tacrolimus for transplants despite the rhetoric. 
 
Conclusion: Stakeholders in the health care field are working together and developing methods to 
increase funding for new valued medicines whilst restricting their use where there are concerns to 
optimise resource use. This will (need to) continue to enable access to safe, (cost-) effective and 
affordable medicines. 
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